J.-E. Trihan , M. De Géa , E.-M. Jutant , E. Larrieu-Ardilouze , C. Beaufort , M. Puyade , D. Montani , C. Thollot , C. Bouleti , D. Lanéelle , M. Croquette
{"title":"Femoral venous stasis index infor prediction of elevated right atrial pressure and mortality in pulmonary hypertension","authors":"J.-E. Trihan , M. De Géa , E.-M. Jutant , E. Larrieu-Ardilouze , C. Beaufort , M. Puyade , D. Montani , C. Thollot , C. Bouleti , D. Lanéelle , M. Croquette","doi":"10.1016/j.acvd.2024.10.097","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Elevated right atrial pressure (RAP) is associated with poor prognosis regarding 1-year mortality in pulmonary hypertension (PH) patients. Unfortunately, there is currently no reliable non-invasive technique for estimating RAP in PH patients. Recently, femoral venous stasis index (FVSI) has been described as highly correlated to RAP in PH patients.</div></div><div><h3>Objective</h3><div>Our goal was to confirm the diagnostic accuracy of FVSI for estimating RAP, and compare the prognostic value of FVSI, RAP and renal venous stasis index (RVSI) at 2 years in PH patients.</div></div><div><h3>Method</h3><div>In this prospective cross-sectional study, we included 101 patients with suspected or known PH undergoing right heart catheterization (RHC) for 18 months. Each included patient underwent DUS of the femoral and renal veins within 4<!--> <!-->hours prior to the RHC, to blindly assess FVSI and RVSI. FVSI and RVSI (no unit) was calculated as the percentage of non anterograde flow time over an index cardiac cycle, during a short apnea ([Index cardiac cycle(ms)<!--> <!-->−<!--> <!-->Anterograde flow time (ms)/Index cardiac cycle(ms)]). For RAP analysis, we chose the cut-off values based on the 2022 ESC/ERS guidelines (RAP<!--> <!--><<!--> <!-->8<!--> <!-->mmHg, 8–14<!--> <!-->mmHg and<!--> <!-->><!--> <!-->14<!--> <!-->mmHg).</div></div><div><h3>Results</h3><div>FVSI was highly correlated to RAP (rs<!--> <!-->=<!--> <!-->0.77, <em>p</em> <!--><<!--> <!-->0.001). On multivariate analysis, only FVSI remained significantly associated with RAP (<em>p</em> <!--><<!--> <!-->0.001) compared to clinical and biological signs, echocardiography and RVSI. With a cutoff of 0.18, FVSI can exclude a RAP<!--> <!-->><!--> <!-->8<!--> <!-->mmHg with an 87% sensitivity (area under ROC curve (AUROC)<!--> <!-->=<!--> <!-->0.88) and, with a cutoff of 0.45, can confirm a RAP<!--> <!-->><!--> <!-->14<!--> <!-->mmHg with a 93% specificity (AUROC<!--> <!-->=<!--> <!-->0.93). During 2-year follow-up, the composite endpoint (hospitalization; increase in PH-treatment and all-cause death) occurred in 32 patients (31.7%). FVSI independently predicted PH morbidity/mortality (FVSI<!--> <!-->≥<!--> <!-->0.45 versus FVSI<!--> <!--><<!--> <!-->0.18: HR<!--> <!-->=<!--> <!-->5.41 [1.53–19.2], <em>p</em> <!-->=<!--> <!-->0.009) (<span><span>Figure 1</span></span>). Inter-observer reproducibility between junior and senior operators was excellent (intraclass coefficient of 0.97 [IC95% 0.95–0.98]).</div></div><div><h3>Conclusion</h3><div>We propose FVSI as the first non-invasive tool for estimating RAP, according to the recommended cut-off values, in PH patients.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 1","pages":"Pages S53-S54"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187521362400442X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Elevated right atrial pressure (RAP) is associated with poor prognosis regarding 1-year mortality in pulmonary hypertension (PH) patients. Unfortunately, there is currently no reliable non-invasive technique for estimating RAP in PH patients. Recently, femoral venous stasis index (FVSI) has been described as highly correlated to RAP in PH patients.
Objective
Our goal was to confirm the diagnostic accuracy of FVSI for estimating RAP, and compare the prognostic value of FVSI, RAP and renal venous stasis index (RVSI) at 2 years in PH patients.
Method
In this prospective cross-sectional study, we included 101 patients with suspected or known PH undergoing right heart catheterization (RHC) for 18 months. Each included patient underwent DUS of the femoral and renal veins within 4 hours prior to the RHC, to blindly assess FVSI and RVSI. FVSI and RVSI (no unit) was calculated as the percentage of non anterograde flow time over an index cardiac cycle, during a short apnea ([Index cardiac cycle(ms) − Anterograde flow time (ms)/Index cardiac cycle(ms)]). For RAP analysis, we chose the cut-off values based on the 2022 ESC/ERS guidelines (RAP < 8 mmHg, 8–14 mmHg and > 14 mmHg).
Results
FVSI was highly correlated to RAP (rs = 0.77, p < 0.001). On multivariate analysis, only FVSI remained significantly associated with RAP (p < 0.001) compared to clinical and biological signs, echocardiography and RVSI. With a cutoff of 0.18, FVSI can exclude a RAP > 8 mmHg with an 87% sensitivity (area under ROC curve (AUROC) = 0.88) and, with a cutoff of 0.45, can confirm a RAP > 14 mmHg with a 93% specificity (AUROC = 0.93). During 2-year follow-up, the composite endpoint (hospitalization; increase in PH-treatment and all-cause death) occurred in 32 patients (31.7%). FVSI independently predicted PH morbidity/mortality (FVSI ≥ 0.45 versus FVSI < 0.18: HR = 5.41 [1.53–19.2], p = 0.009) (Figure 1). Inter-observer reproducibility between junior and senior operators was excellent (intraclass coefficient of 0.97 [IC95% 0.95–0.98]).
Conclusion
We propose FVSI as the first non-invasive tool for estimating RAP, according to the recommended cut-off values, in PH patients.
期刊介绍:
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.